scholarly journals Evaluation of the Potential Association between NOS Gene Polymorphisms (iNOS G-954C and eNOS G894T) and Psoriasis

2016 ◽  
Vol 28 (1) ◽  
pp. 110 ◽  
Author(s):  
Xi Duan ◽  
Yan Cheng ◽  
Linbo Gao ◽  
Lijuan Li ◽  
Tao Wang ◽  
...  
2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Ayako Nishizawa ◽  
Kazuki Kumada ◽  
Keiko Tateno ◽  
Maiko Wagata ◽  
Sakae Saito ◽  
...  

AbstractPreeclampsia is a pregnancy-induced disorder that is characterized by hypertension and is a leading cause of perinatal and maternal–fetal morbidity and mortality. HLA-G is thought to play important roles in maternal–fetal immune tolerance, and the associations between HLA-G gene polymorphisms and the onset of pregnancy-related diseases have been explored extensively. Because contiguous genomic sequencing is difficult, the association between the HLA-G genotype and preeclampsia onset is controversial. In this study, genomic sequences of the HLA-G region (5.2 kb) from 31 pairs of mother–offspring genomic DNA samples (18 pairs from normal pregnancies/births and 13 from preeclampsia births) were obtained by single-molecule real-time sequencing using the PacBio RS II platform. The HLA-G alleles identified in our cohort matched seven known HLA-G alleles, but we also identified two new HLA-G alleles at the fourth-field resolution and compared them with nucleotide sequences from a public database that consisted of coding sequences that cover the 3.1-kb HLA-G gene span. Intriguingly, a potential association between preeclampsia onset and the poly T stretch within the downstream region of the HLA-G*01:01:01:01 allele was found. Our study suggests that long-read sequencing of HLA-G will provide clues for characterizing HLA-G variants that are involved in the pathophysiology of preeclampsia.


2020 ◽  
Author(s):  
Zhili Zou ◽  
Yulan Huang ◽  
Jinyu Wang ◽  
Wenjiao Min ◽  
Bo Zhou

Abstract Background: A number of studies have shown that genetic factor plays an importantrole in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug.Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association.Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p<0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p<0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers.Conclusions: The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.


2020 ◽  
Author(s):  
Zhili Zou ◽  
Yulan Huang ◽  
Jinyu Wang ◽  
Wenjiao Min ◽  
Bo Zhou

Abstract Background: A number of studies have shown that genetic factor plays an important role in etiology of panic disorder (PD). The aim of the present study was to examine the association of serotonin-related gene polymorphisms with PD risk. Then, we analyzed the correlation between these gene polymorphisms and response to sertraline drug. Methods: 233 patients with PD and 231 healthy controls were enrolled in the study. Panic Disorder Severity Scale (PDSS) were administered to all subjects, and all patients in the study were also assessed after 4 weeks of treatment. The SLC6A4(rs140701, rs3813034, 5-HTTLPR and STin2), 5-HTR1A rs6295, 5-HTR2A rs6313 and COMT rs4680 gene polymorphisms were genotyped and assessed for the potential association. Results: The allelic model showed that the SLC6A4 rs140701 polymorphism variant was significantly associated with increased risk of PD (OR = 0.624, 95 % CI 0.450-0.864, p <0.05), and a significant result was found in the dominant model (OR = 0.546; 95% CI, 0.371-0.804, p <0.05). There was a significant difference in allele and genotype frequency between responders and nonresponders in the 5-HTTLPR polymorphism (OR = 0.205, 95 % CI 0.128-0.328; OR = 0.249, 95 % CI 0.155-0.401, both p <0.001), indicating the PD patients with S-allele had a poorer response to sertraline than L-allele carriers. Conclusion s : The present study suggests that the SLC6A4 rs140701 polymorphism variant may be associated with susceptibility to PD, and 5-HTTLPR polymorphism may be a predictor of response to sertraline in the treatment of PD.


2008 ◽  
Vol 55 (5) ◽  
pp. 267-273 ◽  
Author(s):  
Y. Muramatsu ◽  
Y. Sakemi ◽  
M. Horiuchi ◽  
T. Ogawa ◽  
K. Suzuki ◽  
...  

Author(s):  
Л.М. Огородова ◽  
К.Ю. Рукин ◽  
И.В. Петрова ◽  
С.И. Винтизенко

В последние годы все больше внимания уделяется интервенционным способам лечения ИБС. Однако, несмотря на многочисленные клинические исследования остается нерешенным вопрос рестенозирования стентов после интервенционных вмешательств. На сегодняшний день становится актуальным изучение молекулярных механизмов рестенозирования коронарных артерий, а также поиск новых генетически обусловленных предикторов развития рестеноза после стентирования. Воздействие NO-синтаз на развитие дисфункции эндотелия не вызывает сомнения, в то же время исследования, посвященные изучению влияния полиморфизма генов NOS на вероятность рестенозирования в стенте единичны и основаны на небольшом количестве клинических наблюдений. Вышесказанное свидетельствует об актуальности данного исследования, результаты которого сформировали новые представления о роли генов NO-синтаз в формировании предрасположенности к гиперпролиферации стентов у больных с ИБС. Цель работы - выделение диагностически значимых факторов-предикторов рестеноза после стентирования коронарных артерий у паицентов с ИБС и определение их чувствительности и специфичности при помощи ROC-кривых. Методика: в основу данного исследования положены результаты целенаправленного обследования 484 пациентов с верифицированным диагнозом ИБС, находившихся на лечении в отделении атеросклероза и хронической ишемической болезни сердца ФГБНУ «Научно-исследовательский институт кардиологии» СО РАН. Стентирование коронарных артерий было проведено у 210 чел. - группа рестеноза (n = 60) и группа без рестеноза (n = 150). Исследование генотипа проводили путем выделения геномной ДНК из цельной венозной крови обследуемых по стандартной неэнзиматической методике, а также исследования полиморфизмов генов NOS методом полимеразной цепной реакции (ПЦР). Результаты. Установлено 6 предикторов развития рестенозирования после стентирования при ИБС: протяженность стеноза, сужение коронарной артерии (% стеноза), полиморфизм 894G/T, наличие в анамнезе АГ, наличие у больного гаплотипов TCabGT11 и TTabGG11, определена их чувствительность и специфичность при помощи ROC-кривых. Установлено, что в Сибирской популяции у носителей гаплотипа TCabGT11 наиболее вероятно развитие рестенозирования в стенте, а при наличии гаплотипа TTabGG11 риск рестенозирования минимален. Заключение. Полиморфизмы 894 G/T гена eNOS ассоциированы с риском развития рестеноза, что может быть использовано как дополнительные маркеры риска развития рестеноза после стентирования коронарных артерий. In recent years, growing attention has been paid to interventional treatment of ischemic heart disease (IHD). However, despite numerous clinical studies, the issue of in-stent restenosis following interventions remains unsolved. At present, studying molecular mechanisms of coronary restenosis along with searching for new, genetically determined predictors of in-stent restenosis has become relevant. Effects of NO synthases on development of endothelial dysfunction are above any doubt; however, studies focusing on the effect of NOS gene polymorphism on probability of in-stent restenosis are scarce and based on a small number of clinical observations. Therefore, the present study is highly relevant as it has resulted in development of new concepts on the role of NO-synthase genes in predisposition to in-stent hyperproliferation in patients with IHD. The aim of this study was to identify diagnostically significant, predictive factors for in-stent coronary restenosis in patients with ischemic heart disease and to determine their sensitivity and specificity using ROC curves. Methods. This study was based on data from a targeted evaluation of 484 patients with a verified diagnosis of IHD who were managed at the Department of Atherosclerosis and Chronic Ischemic Heart Disease of the Research Institute of Cardiology, Siberian Branch of the Russian Academy of Medical Sciences. Coronary artery stenting was performed for 210 patients divided into two groups, with restenosis (n = 60) and without restenosis (n = 150). The genotype was studied on isolated genomic DNA from whole venous blood using a standard non-enzymatic technique, as well as by studying NOS gene polymorphisms using the polymerase chain reaction (PCR). Results. Six predictors for in-stent restenosis in IHD were identified - stenosis length, per cent narrowing of the coronary artery (% stenosis), 894G/T polymorphism, history of arterial hypertension, presence of TCabGT11 and TTabGG11 haplotypes, and their sensitivity and specificity determined with ROC curves. In the Siberian population, development of in-stent restenosis most likely occurred in carriers of the TCabGT11 haplotype while the risk for restenosis was minimal in the presence of the TTabGG11 haplotype. Сonclusion. The 894 G/T eNOS gene polymorphisms are associated with a risk for restenosis and might be used as additional markers for the risk of restenosis following coronary stenting.


2000 ◽  
Vol 18 ◽  
pp. S57
Author(s):  
Y. Miyamoto ◽  
Y. Saito ◽  
M. Yoshimura ◽  
M. Nakayama ◽  
Y. Shimasaki ◽  
...  

2019 ◽  
Vol 2019 ◽  
pp. 1-8 ◽  
Author(s):  
Qin Li ◽  
Peng Zhang ◽  
Yanyun Wang ◽  
Yan Zhang ◽  
Kai Li ◽  
...  

Background. Previous evidence has indicated that the reduction of axis inhibition protein 1 (AXIN1) expression is related with the poor differentiation of non-small-cell lung cancer (NSCLC). However, the potential association between AXIN1 and bladder cancer (BC) is unknown. We aimed to initially explore the relevance of AXIN1 gene polymorphisms (rs12921862 C/A, rs1805105 T/C, and rs370681 C/T) and BC. Methods. Three hundred and sixteen BC patients and 419 healthy controls had been enrolled. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method was used for genotyping three tag single-nucleotide polymorphisms (SNPs) of AXIN1. The SNPstats online analysis software and SPSS software were used for statistical analysis. Results. Our data revealed that three tag SNPs were associated with an increased risk of BC (rs12921862: P<0.001, OR 95%CI=4.61 (3.13-6.81); rs1805105: P=0.046, OR 95%CI=1.35 (1.00-1.82); and rs370681: P=0.004, OR 95%CI=1.56 (1.15-2.10)). For rs12921862, A allele was an independently protective factor which correlated with a better prognosis in non-muscle-invasive bladder cancer (NMIBC) patients (P=0.03, OR 95%CI=0.10 (0.01-0.84)). Stratification analysis demonstrated that rs370681 polymorphism was related with high-grade bladder cancer (P=0.04, OR 95%CI=1.85 (1.04-3.23)). Conclusion. The AXIN1 gene polymorphisms might implicate in BC risk, and rs12921862 could be a potential forecasting factor for prognosis of BC patients.


Sign in / Sign up

Export Citation Format

Share Document